Awards to John Newman and Pankaj Kapahi will enable preclinical research in #ketone bodies and #glycation management. Thanks Hevolution Foundation! https://lnkd.in/gBSUmz6u
Buck Institute for Research on Aging’s Post
More Relevant Posts
-
Molecular Biologist | Head of Laboratory Operations | Molecular Biology Lab In-Charge | Consultant | Expert in Molecular Lab Setup | Experienced Leader | Let's Connect!
Heart-on-Chip: The Next Generation of Cardiovascular Research Tools Cardiovascular diseases often stem from a mix of genetics, environment, and medication. To combat this, Heart-on-Chip (HOC) systems are emerging as a groundbreaking tool, outpacing traditional methods like 2D cultures and animal models. HOCs mirror human heart tissue's biology and physiology, offering a cost-effective and efficient platform for drug testing and disease modeling. Recent advances include pumpless HOCs for user-friendly designs and platforms capable of recording electrophysiological data. The review cited below provides an excellent exploration of Heart-on-Chip (HOC) technology, from cellular resources to biomaterials and biosensors, and its promise for transforming cardiovascular research and drug development. Check it out for more details. #HeartOnChip #CardiovascularResearch #Biotechnology #Innovation #Biomaterial #Bioprinting #3Dmodels #Biosensors https://lnkd.in/gDmCQpUm
Step-by-step fabrication of heart-on-chip systems as models for cardiac disease modeling and drug screening
sciencedirect.com
To view or add a comment, sign in
-
We are happy to announce that Klaus Wirth co-authored a paper published in the Journal of Translational Medicine about the "Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone". This is also a step towards understanding the mechanism of a potential biomarker for ME/CFS. In this paper the authors explain how TRPM3 dysfunction (loss of ion channel function) could be involved in ME/CFS as a risk factor by its expression in small nerve fibers and the brain apart from its expression in natural killer cells. The mild or moderate therapeutic effect of low-dose naltrexone thus has a comprehensible physiological and pathophysiological base.🧪📘 https://lnkd.in/e5CXRy_T #mitodicure #lifesciences #media #news #venturecapital #biotech #pharma #innovation #healthcare #MECFS
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone - Journal of Translational Medicine
translational-medicine.biomedcentral.com
To view or add a comment, sign in
-
#ICYMI, last week we published exciting data in Science Translational Medicine, representing the culmination of years of hard work here at NMD Pharma. With this recent publication, we are one step closer to achieving a future where people with #NeuromuscularDiseases can improve their muscle strength, power and endurance to live better, more independent lives. In the video below, our CEO and corresponding author on the paper, Thomas Holm Pedersen, gives insight into NMD670, NMD Pharma’s lead development candidate. This is the first clinical proof-of-mechanism that our ClC-1 inhibitor oral therapy can restore skeletal muscle function in animal models and patients with myasthenia gravis (#MG). Importantly, this new muscle-targeted therapeutic approach has the potential to improve symptoms in other neuromuscular diseases stemming from compromised neurotransmission to skeletal muscles. Watch the full video here: https://lnkd.in/dec5_-sX #NeuromuscularDisease #Biotech #Innovaiton #RareDisease #Myastheniagravis
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine — NMD Pharma
nmdpharma.com
To view or add a comment, sign in
-
📢 We are excited to present our new collection, "Exploring Novel In Vitro Models for Cystic Fibrosis Research," now open for submissions! 🚀🔬 https://lnkd.in/d75Z3Rkq Cystic fibrosis (CF) is a complex genetic disorder affecting the respiratory and digestive systems, often leading to chronic lung inflammation and pathogen infections. Current animal models face limitations in replicating CF's human complexities, highlighting the need for innovative in vitro approaches. With the recent approval of the “FDA Modernization ACT 2.0,” the use of complex in vitro cultures for drug testing is now a reality, offering more accurate research alternatives. This collection, led by Dr. Roberto Plebani, Dr. Yuncheng M. and, Dr. Domenico Mattoscio, welcomes articles focusing on novel in vitro models for CF research, with a particular interest in papers exploring 3D in vitro models, like organoids and organ-on-a-chip technology, which can enhance drug delivery predictions and provide insights into inflammation dynamics. 📃 Register your interest here: https://lnkd.in/di2q-s58 Manuscript Submission Deadline: 31 January 2025 #CysticFibrosis #CFResearch #InVitroModels #Organoids #OrganOnAChip #DrugDiscovery #Pharmacology #Research #InnovativeScience
To view or add a comment, sign in
-
There are so many rodent models available for preclinical target and drug discovery for #MASH. But which model offers the highest resemblance of the human disease? The answer is simple. In the recent issue of Nature Metabolism, the renowned #LITMUS consortium concludes that Gubra’s GAN DIO-MASH mouse model ranks #1 for human proximity, a key indicator of clinical translatability, in terms of both metabolic relevance and ability to induce MASH-fibrosis. LITMUS compared a wide range of the most commonly used preclinical MASH models, evaluating their metabolic phenotype, liver histopathology and transcriptomics against corresponding MASH patient data. We are very proud and grateful to be recognized by LITMUS as the provider of the most translational preclinical model. Check out the paper and explore the objective ranking of preclinical models of MASH in the industry. #PreclinicalModel #PreclincalResearch #ClinicalTranslatability #MASLD #Publication #PreclinicalCRO #ResearchModels
To view or add a comment, sign in
-
Get the best from your microglia! We're here to help. At Axol, we've spent more than a decade at the forefront of iPSC technology, adding to our bank of expertise in using iPSC-derived cells for drug discovery and research. Our straightforward workflows and simple to read protocols ensure you get the best from your cells, and we are always on hand to support you in achieving your goals. Human iPSC-derived microglia are made by differentiating iPSCs from reprogrammed donor blood samples. They retain the phenotypic characteristics of the donor, producing a more human-relevant model system which opens up exciting applications of disease-derived microglia to test potential therapies in specific human disease models. Our Scientific Group Leader, Jessica Tilman PhD., is deeply involved in both microglia based product development and the delivery of service projects. Jessica works in the cellular science group, and regularly participates in custom service projects, testing compounds on healthy and disease lines for disease specific phenotypes. Jessica is happy to share her hard-won experience of working with microglia - here are her top tips: 1. Microglia are easily activated, so if you are replating, rest time is recommended before using them for assays. 2. Allow 7 days from thaw before using cells, and ensure the thawing process is as quick as possible to avoid loss of viability 3. For best results, seed cells directly onto a plate that is assay ready Click here to read the Cryopreserved Mature Microglia User Guide : https://hubs.la/Q02KPYzc0 Or click here to watch the Tech Clinic: https://hubs.la/Q02KPSbS0 If you would like to use axoCells microglia to develop human-relevant models for drug discovery and research, contact us at [email protected] #iPSCs #microglia #DrugDiscovery #StemCells #biopharma
To view or add a comment, sign in
-
The buildup of amyloid beta (Aβ) peptides in the brain leads to cognitive decline and memory loss associated with Alzheimer's disease (AD). It's been suggested that the smaller soluble Aβ monomers are more detrimental to healthy brain function than larger Aβ plaques. However, recent breakthroughs suggest that disrupting plaque formation may hinder the progression of Alzheimer’s. IGC Pharma has developed a patent-pending molecule, TGR-63, which disrupts intermolecular interactions between Aβ peptides. This destabilize assembly and prevents the formation of plaques. In preclinical studies, TGR-63 reduced amyloid load in transgenic AD mice. Last year, the FDA approved the use of Lecanemab, an anti-Aβ drug that reduces aggregated Aβ, for the treatment of Alzheimer’s with mild cognitive impairment. It will be interesting to see how TGR-63 performs in clinical trials. The impact of Aβ removing compounds on soluble monomers is a question that remains to be answered. Stay tuned as we continue to follow the latest developments in Alzheimer's research. #AlzheimersDisease #MedicalResearch #Dementia #AlzheimersResearch #BreakThroughStudy #Aβ #AmyloidBeta
To view or add a comment, sign in
-
𝐈𝐍𝐇𝐈𝐁𝐈𝐓𝐈𝐎𝐍 𝐎𝐅 𝐂𝐈𝐑𝐂𝐑𝐍𝐀 𝐀𝐒𝐏𝐇: 𝐀 𝐌𝐈𝐋𝐄𝐒𝐓𝐎𝐍𝐄 𝐈𝐍 𝐇𝐄𝐏𝐀𝐓𝐈𝐂 𝐅𝐈𝐁𝐑𝐎𝐒𝐈𝐒 𝐑𝐄𝐒𝐄𝐀𝐑𝐂𝐇 A recent publication in Elsevier's Biochemical Pharmacology, titled "Inhibition of circular RNA ASPH reduces the proliferation and promotes the apoptosis of hepatic stellate cells in hepatic fibrosis," is a testament to the strides being made in molecular medicine. This research, led by a team of experts including Hongwu Meng, Lingfeng Jiang, Pengcheng Jia, Ruowen Niu, Fangtian Bu, Yan Zhu, Xueyin Pan, Juanjuan Li, Jinyu Liu, Yilong Zhang, Cheng Huang, Xiongwen Lv, and Jun Li, represents a significant leap in understanding the complex mechanisms of hepatic fibrosis. 𝑲𝒆𝒚 𝑰𝒏𝒔𝒊𝒈𝒉𝒕𝒔 𝒇𝒓𝒐𝒎 𝒕𝒉𝒆 𝑺𝒕𝒖𝒅𝒚 The study brings to light the critical role of a novel circRNA, ASPH, in the pathogenesis of hepatic fibrosis (HF). Through innovative approaches, the team demonstrated the significant upregulation of circASPH in HF, unveiling its role in regulating hepatic stellate cell activity via the miR-139-5p/Notch1 axis. 𝑴𝒆𝒕𝒉𝒐𝒅𝒐𝒍𝒐𝒈𝒚 𝒂𝒏𝒅 𝑰𝒎𝒑𝒍𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 Employing cutting-edge techniques such as circRNA-sequencing, luciferase reporter assays, and RNA pull-down, the researchers provided compelling evidence of circASPH's interaction with miR-139-5p. Their findings reveal that reducing circASPH levels can inhibit hepatic stellate cell activation, induce apoptosis, and lessen liver fibrogenic injury, offering a novel therapeutic target in HF. 𝑨𝒅𝒗𝒂𝒏𝒄𝒊𝒏𝒈 𝒕𝒉𝒆 𝑭𝒊𝒆𝒍𝒅: 𝑨 𝑺𝒕𝒆𝒑 𝑻𝒐𝒘𝒂𝒓𝒅𝒔 𝑵𝒐𝒗𝒆𝒍 𝑻𝒉𝒆𝒓𝒂𝒑𝒊𝒆𝒔 This research not only deepens our understanding of HF but also opens up new possibilities for diagnosis and treatment. The identification of circASPH as a potential biomarker for HF is particularly promising, paving the way for more targeted and effective therapeutic strategies. #BiochemicalPharmacology #circRNA #HepaticFibrosis #MedicalInnovation #ResearchExcellence #ScientificBreakthrough #HealthcareFuture #MolecularMedicine
To view or add a comment, sign in
-
#MeetTheResearcher Introducing Kalina Naidoo from Wade-Martins Lab this week. Kalina is a #postdoc #researcher investigating molecular phenotypes in sporadic #ParkinsonsDisease patient derived #fibroblasts. Kalina's GSK-funded project is based on work by Michele Hu and her clinical team, that postulates that Parkinson’s Disease (PD) has 4 clusters based on their clinical symptoms (motor dysfunction presentation (unilateral or bilateral), non-motor dysfunction, disease progression, and response to levodopa treatment). Working alongside Professor Richard Wade-Martins and Dr Brent Ryan, Kalina will be investigating molecular differences in the fibroblasts (skin cells) of 100 PD patients (across all subtypes). Kalina will be focusing on elements of the cell responsible for recycling (lysosomes) and energy management (mitochondria). PD is noted by a loss of dopamine producing neurons (potentially due to energy mismanagement) in the brain and accumulation of toxic aggregated protein, alpha-synuclein (potentially due to recycling malfunction). Determining the biological underpinning of the clusters may allow for a more refined therapeutic approach, as some clusters may have stronger lysosomal dysfunction, whilst others more mitochondrial, and this informs them on what pathways to pharmacologically target, and this will hopefully lead to better outcomes for patients.
To view or add a comment, sign in
-
Recent research has introduced new treatments and diagnostic tools, showing promising results, including #Leqembi (Lecanemab), #Simufilam, #AR1001 and many others. These advancements bring new hope for AD patients, although clinical application still faces challenges. Learn more about these advancements in AD treatment and diagnosis 👉 https://bit.ly/3XwlxVv #AlzheimersDisease #NeurodegenerativeDiseases #HealthcareInnovation #ADResearch #Biotech #MedicalResearch
Breaking Ground in Alzheimer's with 10 Cutting-Edge Treatments Paving the Way in 2024 - GeneOnline News
geneonline.com
To view or add a comment, sign in
16,421 followers